DR info

臨床試験数 : 9 / 薬物数 : 5 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 51

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Afinitor (everolimus)
   Yonsei University
      2018   Phase 2   NCT03198949   Korea, Republic of;
Classical ketogenic diet
   University College, London
      2014   -   NCT02261753   Austria;Belgium;Czech Republic;Czechia;France;Germany;Italy;Switzerland;United Kingdom;United States;
Everolimus
   NYU Langone Health
      2014   Phase 2   NCT02451696   United States;
Gold
   Beijing Tiantan Hospital, Capital Medical University
      2020   Phase 0   ChiCTR2100046183   China;
Sirolimus
   Hokkaido University Hospital
      2018   -   JPRN-UMIN000030962   Japan;
   Hokkaido University HospitalNishi-Niigata Chuo National HospitalNational Center Hospital, NCNPShizuoka Institute of Epilepsy and Neurological DisordersOkayama University Hospital
      2018   Phase 2   JPRN-UMIN000033504   Japan;
   Kato Mitsuhiro
      2019   Phase 2   JPRN-jRCTs031190157   Japan;
   National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO
      2017   Phase 2   JPRN-UMIN000030797   Japan;
   Takahashi Yukitoshi
      2019   Phase 2   JPRN-jRCTs041190059   Japan;